Page 81 - Read Online

Page 12 Moore et al. J Transl Genet Genom 2021;5:200-217 https://dx.doi.org/10.20517/jtgg.2021.08

studies are needed to further elucidate the role of recessive variation in NHL risk.

In conclusion, we provide new evidence for the role of recessive genetic variation in the risk of CLL and FL
in outbred European-ancestry populations. The knowledge that recessive variation in disease susceptibility
to NHL is likely to be present suggests that further studies should be undertaken to identify the specific loci
responsible for the associations reported here. As GWAS increase in sample size, they will have greater
statistical power to identify recessive genetic variants-associated risk and further characterize the underlying
genetic architecture of specific NHL subtypes.

DECLARATIONS
Acknowledgements
ATBC - The ATBC Study is supported by the Intramural Research Program of the United States National
Cancer Institute, National Institutes of Health, Department of Health and Human Services.
BCCA - Canadian Institutes for Health Research (CIHR); Canadian Cancer Society; Michael Smith
Foundation for Health Research.
CPS-II - The Cancer Prevention Study-II (CPS-II) Nutrition Cohort is supported by the American Cancer
Society. Genotyping for all CPS-II samples were supported by the Intramural Research Program of the
National Institutes of Health, NCI, Division of Cancer Epidemiology and Genetics. The authors would also
like to acknowledge the contribution to this study from central cancer registries supported through the
Centers for Disease Control and Prevention National Program of Cancer Registries, and cancer registries
supported by the National Cancer Institute Surveillance Epidemiology and End Results program.
ELCCS - Blood Cancer UK, United Kingdom.
ENGELA - Association pour la Recherche contre le Cancer (ARC), Institut National du Cancer (INCa),
Fondation de France, Fondation contre la Leucémie, Agence nationale de sécurité sanitaire de
l’alimentation, de l’environnement et du travail (ANSES).
EPIC - Coordinated Action (Contract #006438, SP23-CT-2005-006438); HuGeF (Human Genetics
Foundation), Torino, Italy; Cancer Research UK. The coordination of EPIC is financially supported by the
European Commission (DG-SANCO) and the International Angency for Research on Cancer. The national
cohorts are supported by the Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave
Roussy, Mutuelle Générale de l'Education National, Institut National de la Santé et de la Recherche Médicale
(INSERM) (France); German Cancer Aid, German Cancer Research Centre (DKFZ), Federal Ministry of
Education and Research (BMBF), Deutsche Krebshilfe, Deutsches Krebsforschungszentrum and Federal
Ministry of Education and Research (Germany); the Hellenic Health Foundation (Greece); Associazione
Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy); Dutch Ministry of
Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch
Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF),
Statistics Netherlands (The Netherlands); ERC-2009-AdG 232997 and Nordforsk, Nordic Centre of
Excellence programme on Food, Nutrition and Health (Norway); Health Research Fund (FIS), PI131/00061
to Granada, PI13/01162 to EPIC-Murcia, Regional Governments of Andalucía, Asturias, Basque Country,
Murcia (no. 6236) and Navarra, ISCIII RETIC ((RD06/0020) (Spain); Swedish Cancer Society, Swedish
Research Council and Country Councils of Skåne and Västerbotten (Sweden); Cancer Research UK [14136
to K.T. Khaw, N.J. Wareham; C570/A16491 to RCT and C8221/A19170 to T. Key (EPIC-Oxford)], Medical
Research Council [10001433 to K.T. Khaw, N.J. Wareham, MR/M012190/1 to T. Key (EPIC-Oxford)]
(United Kingdom).
EpiLymph - European Commission (grant references QLK4-CT-2000-00422 and FOOD-CT-2006-023103);
We thank CERCA programme/Generalitat de Catalunya for institutional support. This work was supported
by Spanish Ministry of Economy and Competitiveness - Carlos III Institute of Health cofunded by FEDER
funds/European Regional Develpment Fund (ERDF) - a way to build Europe (grant references CIBERESP,
PI17/01280, PI20/00288) with the support of the Secretariat for Universities and Research of the Ministry of